Roche Sees Biomarker Data As Support For Immuno-Oncology Strategy
Use of PD-L1 expression as a biomarker may be up for debate at ASCO, but Roche assures analysts that proper application will unlock its combination-heavy development strategy.
Use of PD-L1 expression as a biomarker may be up for debate at ASCO, but Roche assures analysts that proper application will unlock its combination-heavy development strategy.